News
Novo's Wegovy picks up 3rd indication with key FDA approval in the liver disease MASH
With a new endorsement from the FDA, Novo Nordisk’s Wegovy has picked up its third indication and become the second drug approved in a severe form of fatty liver disease. | The FDA has signed off on an accelerated approval for Novo Nordisk's Wegovy to treat certain adults with metabolic-associated steatohepatitis.
The Food and Drug Administration approved the weight loss drug Wegovy to treat an increasingly prevalent liver disease on ...
Zacks.com on MSN3m
NVO Wins FDA Approval for MASH Treatment: ETFs Likely to Gain
NVO rose about 4% on Aug. 18, 2025, after Wegovy won FDA approval as the first GLP-1 therapy for MASH, expanding its reach ...
Wegovy is now approved by the FDA to treat metabolic-associated steatohepatitis in adults with moderate-to-advanced fibrosis ...
The approval was based on Part 1 (72 week data) of the randomized, double-blind, placebo-controlled phase 3 ESSENCE trial.
Zacks Investment Research on MSN20h
NVO Stock Up on FDA Nod for Wegovy in MASH: More Upside Ahead?
Novo Nordisk NVO announced that the FDA has granted accelerated approval to its blockbuster GLP-1 drug, Wegovy (semaglutide 2 ...
Health and Me on MSN9h
Wegovy Approved For MASH Treatment With Fibrosis But No Cirrhosis
FDA has approved Novo Nordisk's Wegovy, one-weekly 2.4 mg semaglutide injection for treating metabolic-associated ...
The glucagon-like peptide-1 (GLP-1) receptor agonist gained accelerated approval for patients with MASH and moderate to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback